12 Health Care Stocks Moving In Friday's After-Market Session
GainersLantern Pharma (NASDAQ:LTRN) shares rose 14.3% to $7.04 during Friday's after-market session. The company's market cap stands at $75.7 million. As per the press release, Q1 earnings came out ye
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As...
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November
Alterity Therapeutics (ASX:ATH) said the second phase of its ATH434-201 study is on track for completion in November after receiving the greenlight from an independent Data Monitoring Committee, accor
JPMorgan Chase Ends Major Stake in Alterity Therapeutics
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersHelius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million. Vaxxinity (NASDAQ:VAXX) shares moved up
BNYMC Ups Stake in Alterity Therapeutics
Alterity Therapeutics Gains Momentum in Q3
Alterity Therapeutics' ATH434 Shows Treatment Promise
Alterity Therapeutics Adds New Shares Post-Options
Alterity Therapeutics Aims for ASX Listing Boost
Alterity Therapeutics' Breakthrough in Rare Disease Treatment
Alterity Therapeutics Announced Presentation Of New Data Demonstrating Potential Of ATH434 To Treat Rare Neurodegenerative Disease Friedreich's Ataxia
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc
Alterity Therapeutics Showcases Promising Neurodegenerative Drug Data
Alterity Therapeutics Unveils Promising Neurological Data
Alterity Therapeutics Expands Securities Quotation
12 Health Care Stocks Moving In Monday's After-Market Session
GainersDynatronics (NASDAQ:DYNT) stock increased by 70.1% to $0.63 during Monday's after-market session. The company's market cap stands at $3.0 million. Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock r
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
No Data